Prophylaxis of Cytomegalovirus Infection in Solid Organ Transplantation, Retrospective Evaluation

IF 0.1 Q4 TRANSPLANTATION Transplant Research and Risk Management Pub Date : 2022-06-01 DOI:10.2147/trrm.s366213
Abdulkareem M. Albekairy, M. Shawaqfeh, Shroug H Alharbi, Faisal Almuqbil, Mesfer A Alghamdi, Nataleen A Albekairy, S. Muflih, Abdulmalik A Alkatheri
{"title":"Prophylaxis of Cytomegalovirus Infection in Solid Organ Transplantation, Retrospective Evaluation","authors":"Abdulkareem M. Albekairy, M. Shawaqfeh, Shroug H Alharbi, Faisal Almuqbil, Mesfer A Alghamdi, Nataleen A Albekairy, S. Muflih, Abdulmalik A Alkatheri","doi":"10.2147/trrm.s366213","DOIUrl":null,"url":null,"abstract":"Introduction: Cytomegalovirus infection is one of the opportunistic infections that occur within the first year of solid organ transplantation (SOT). Antiviral prophylaxis like valganciclovir is recommended for organ transplant recipients if the donors are seropositive. The study aims to assess the association between compliance with CMV prevention guidelines and the incidence of CMV infection post kidney and liver transplantation. Methods: A single-center, cross-sectional chart review study was conducted at a tertiary care facility. The study included patients with liver and/or kidney transplantation and received valganciclovir for CMV prevention. The primary endpoint is to determine the incidence of CMV post SOT. The secondary endpoint is to assess the association between compliance with the CMV prevention guidelines and the incidence of CMV infection. Descriptive statistics were used to report the incidence of CMVand logistic regression for risk factor comparisons. The study was approved by the Institutional Review Board. Results: A total of 493 patients had a mean age of 48.6 ± 15.3 years were included. For the primary endpoint, there were a total of 257 patients with CMV occurrence (52.1%). For the secondary endpoint, there was no statistically significant association between CMV incidence and starting CMV prophylaxis agent post-transplantation within 10 days post-transplant (p < 0.75) and duration of CMV prophylactic medications (p < 0.47). In this study, the cases of CMV disease that occurred within 3–6 months following completion of antiviral prophylaxis were in 28% of the patients. Other factors associated with increased risk of CMV infection were evaluated. Conclusion: We found about 28% of CMV infection cases occurred within 3–6 months following completion of antiviral prophylaxis. This was attributed to non-adherence to prophylaxis guidelines. The study has shown that there is a need for improvement in clinical practice. Future studies should address the optimal duration of the CMV prophylaxis. to identify the factors associated with the development of CMV among transplant patients. The adjusted odds ratios (AORs) and 95% confidence intervals (CIs) were established. The statistical significance was set as α=0.05. All statistical analyses were performed using Statistical Package for Social Sciences version 24.0 (SPSS 24.0).","PeriodicalId":41597,"journal":{"name":"Transplant Research and Risk Management","volume":" ","pages":""},"PeriodicalIF":0.1000,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transplant Research and Risk Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/trrm.s366213","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"TRANSPLANTATION","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Cytomegalovirus infection is one of the opportunistic infections that occur within the first year of solid organ transplantation (SOT). Antiviral prophylaxis like valganciclovir is recommended for organ transplant recipients if the donors are seropositive. The study aims to assess the association between compliance with CMV prevention guidelines and the incidence of CMV infection post kidney and liver transplantation. Methods: A single-center, cross-sectional chart review study was conducted at a tertiary care facility. The study included patients with liver and/or kidney transplantation and received valganciclovir for CMV prevention. The primary endpoint is to determine the incidence of CMV post SOT. The secondary endpoint is to assess the association between compliance with the CMV prevention guidelines and the incidence of CMV infection. Descriptive statistics were used to report the incidence of CMVand logistic regression for risk factor comparisons. The study was approved by the Institutional Review Board. Results: A total of 493 patients had a mean age of 48.6 ± 15.3 years were included. For the primary endpoint, there were a total of 257 patients with CMV occurrence (52.1%). For the secondary endpoint, there was no statistically significant association between CMV incidence and starting CMV prophylaxis agent post-transplantation within 10 days post-transplant (p < 0.75) and duration of CMV prophylactic medications (p < 0.47). In this study, the cases of CMV disease that occurred within 3–6 months following completion of antiviral prophylaxis were in 28% of the patients. Other factors associated with increased risk of CMV infection were evaluated. Conclusion: We found about 28% of CMV infection cases occurred within 3–6 months following completion of antiviral prophylaxis. This was attributed to non-adherence to prophylaxis guidelines. The study has shown that there is a need for improvement in clinical practice. Future studies should address the optimal duration of the CMV prophylaxis. to identify the factors associated with the development of CMV among transplant patients. The adjusted odds ratios (AORs) and 95% confidence intervals (CIs) were established. The statistical significance was set as α=0.05. All statistical analyses were performed using Statistical Package for Social Sciences version 24.0 (SPSS 24.0).
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
实体器官移植中巨细胞病毒感染的预防,回顾性评价
引言:巨细胞病毒感染是发生在实体器官移植(SOT)第一年内的机会性感染之一。如果供体血清呈阳性,则建议器官移植受者进行抗病毒预防,如缬更昔洛韦。本研究旨在评估肾和肝移植后遵守CMV预防指南与CMV感染发生率之间的关系。方法:在三级护理机构进行单中心横断面图回顾研究。该研究包括接受肝和/或肾移植并接受缬更昔洛韦预防CMV的患者。主要终点是确定SOT后CMV的发生率。次要终点是评估遵守CMV预防指南与CMV感染发生率之间的关系。使用描述性统计报告CMV的发生率,并使用逻辑回归进行危险因素比较。这项研究得到了机构审查委员会的批准。结果:纳入493例患者,平均年龄48.6±15.3岁。就主要终点而言,共有257名患者出现CMV(52.1%)。就次要终点而言,CMV发生率与移植后10天内开始使用CMV预防剂(p<0.75)和CMV预防药物的持续时间(p<0.47)之间没有统计学上的显著关联。在本研究中,在完成抗病毒预防后3-6个月内发生的CMV疾病病例占28%。评估了与CMV感染风险增加相关的其他因素。结论:我们发现大约28%的CMV感染病例发生在抗病毒预防完成后的3-6个月内。这归因于未遵守预防指南。这项研究表明,临床实践需要改进。未来的研究应该解决CMV预防的最佳持续时间。以确定与移植患者中CMV发展相关的因素。建立了调整后的比值比(AOR)和95%置信区间(CI)。统计显著性设定为α=0.05。所有统计分析均使用社会科学统计软件包24.0版(SPSS 24.0)进行。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
0.70
自引率
0.00%
发文量
6
审稿时长
16 weeks
期刊最新文献
Tacrolimus Trough Level Variation and Its Correlation to Clinical Outcomes and Consequences in Solid Organ Transplantation Kidney Transplant Recipients with JC Virus Infection Have Decreased Function of the Transplanted Kidney A Unique Case of Tacrolimus-Induced Dysphagia and Dysarthria in the Absence of Diagnostic Findings Predictive Value of Delayed Graft Function Definitions Following Donation After Circulatory Death Renal Transplantation in the United Kingdom Prophylaxis of Cytomegalovirus Infection in Solid Organ Transplantation, Retrospective Evaluation
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1